Shopping Cart
Remove All
Your shopping cart is currently empty
Axl-IN-17 (compound 13c) is an orally active and selective AXL inhibitor with an IC50 value of 3.0 nM, demonstrating antitumor activity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | Axl-IN-17 (compound 13c) is an orally active and selective AXL inhibitor with an IC50 value of 3.0 nM, demonstrating antitumor activity. |
| In vitro | Axl-IN-17 inhibits multiple kinases, including TYRO3, MER, MET, and RON, at a concentration of 1 μM. In BaF3/TEL-AXL cells, it demonstrates antiproliferative activity with an IC50 value of less than 1 nM. Axl-IN-17 (1 nM, 2 h) also suppresses AXL phosphorylation and its downstream signaling pathways. |
| In vivo | Axl-IN-17 (oral, 3 mg/kg, once daily) exhibits favorable pharmacokinetic properties, with a half-life of 10.09 hours and an AUC value of 59815 ng•h/mL. Axl-IN-17 (p.o., 25, 50, 100 mg/kg, once daily, for seven days) shows anti-tumor effects in AXL-driven tumor xenograft mice. |
| Molecular Weight | 563.60 |
| Formula | C32H27F2N7O |
| Cas No. | 3048409-80-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.